Estado del arte: Terapias regenerativas en insuficiencia ovárica prematura (IOP). Revisión Sistemática
DOI:
https://doi.org/10.47464/MetroCiencia/vol33/3/2025/13-27Palabras clave:
insuficiencia ovárica prematura, células madre mesenquimales, plasma rico en plaquetas, terapia regenerativa, foliculogénesis, bioimpresión 3DResumen
La insuficiencia ovárica prematura (IOP) es una condición caracterizada por la pérdida prematura de la función ovárica antes de los 40 años, afectando la fertilidad y la homeostasis endocrina. Las opciones terapéuticas convencionales, como la terapia hormonal sustitutiva (THS) y la donación de ovocitos, no restauran la función ovárica. En este contexto, las terapias regenerativas basadas en células madre mesenquimales (CMM) y plasma rico en plaquetas (PRP) han surgido como enfoques innovadores con potencial para reactivar la foliculogénesis y mejorar la función ovárica.Descargas
Citas
European Society for Human Reproduction and Embryology Guideline Group on Premature Ovarian Insufficiency, Webber L, Davies M, Anderson R, Bartlett J, Braat D, et al. ESHRE Guideline: management of women with premature ovarian insufficiency. Hum Reprod. 2016;31(5):926–937.
Wu X, Cai H, Kallianpur A, Li H, Yang G, Gao J, et al. Impact of premature ovarian failure on mortality and morbidity among Chinese women. PLoS One. 2014;9(3):e89597.
Bentzen JG, Forman JL, Larsen EC, Pinborg A, Johannsen TH, Schmidt L, et al. Maternal menopause as a predictor of anti-Müllerian hormone level and antral follicle count in daughters during reproductive age. Hum Reprod. 2013;28(1):247–255.
Ossewaarde ME, Bots ML, Verbeek AL, Peeters PH, van der Graaf Y, Grobbee DE, et al. Age at menopause, cause-specific mortality and total life expectancy. Epidemiology. 2005;16(4):556–562.
Coulam CB, Adamson SC, Annegers JF. Incidence of premature ovarian failure. Obstet Gynecol. 1986;67(4):604–606.
Golezar S, Ramezani Tehrani F, Khazaei S, Ebadi A, Keshavarz Z. The global prevalence of primary ovarian insufficiency and early menopause: a meta-analysis. Climacteric. 2019;1–9.
Casper RF. Clinical manifestations and diagnosis of menopause. UpToDate. 2011.
Driscoll MA, Davis MC, Aiken LS, Yeung EW, Sterling EW, Vanderhoof V, et al. Psychosocial vulnerability, resilience resources, and coping with infertility: a longitudinal model of adjustment to primary ovarian insufficiency. Ann Behav Med. 2016;50(2):272–284.
Yen SSC. Reproductive Endocrinology. W.B. Saunders, Harcourt Asia; 2001.
De Vos M, Devroey P, Fauser BC. Primary ovarian insufficiency. Lancet. 2010;376(9744):911–921.
Nelson LM. Clinical practice. Primary ovarian insufficiency. N Engl J Med. 2009;360(6):606–614.
Wang S, Sun M, Yu L, Wang Y, Yao Y, Wang D. Niacin inhibits apoptosis and rescues premature ovarian failure. Cell Physiol Biochem. 2018;50(6):2060–2070.
Lumsden MA, Davies M, Sarri G, GDG for MDaMNCGN. Diagnosis and management of menopause: the National Institute of Health and Care Excellence (NICE) Guideline. JAMA Intern Med. 2016;176(8):1205–1206.
Abd-Allah SH, Shalaby SM, Pasha HF, El-Shal AS, Raafat N, Shabrawy SM, et al. Mechanistic action of mesenchymal stem cell injection in the treatment of chemically induced ovarian failure in rabbits. Cytotherapy. 2013;15:64–75.
Abreu SC, Weiss DJ, Rocco PR. Extracellular vesicles derived from mesenchymal stromal cells: a therapeutic option in respiratory diseases? Stem Cell Res Ther. 2016;7:53.
Ame-Thomas P, Maby-El Hajjami H, Monvoisin C, Jean R, Monnier D, Caulet-Maugendre S, et al. Human mesenchymal stem cells isolated from bone marrow and lymphoid organs support tumor B-cell growth: role of stromal cells in follicular lymphoma pathogenesis. Blood. 2007;109:693–702.
Bachelot A, Rouxel A, Massin N, Dulon J, Courtillot C, Matuchansky C, et al. Phenotyping and genetic studies of 357 consecutive patients presenting with premature ovarian failure. Eur J Endocrinol. 2009;161:179–187.
Bao R, Xu P, Wang Y, Wang J, Xiao L, Li G, et al. Bone marrow-derived mesenchymal stem cells transplantation rescues premature ovarian insufficiency induced by chemotherapy. Gynecol Endocrinol. 2018;34:320–326.
Ben-Ami E, Berrih-Aknin S, Miller A. Mesenchymal stem cells as an immunomodulatory therapeutic strategy for autoimmune diseases. Autoimmun Rev. 2011;10:410–415.
Bernardo ME, Zaffaroni N, Novara F, Cometa AM, Avanzini MA, Moretta A, et al. Human bone marrow-derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms. Cancer Res. 2007;67:9142–9149.
Binder AK, Rodriguez KF, Hamilton KJ, Stockton PS, Reed CE, Korach KS. The absence of ER-beta results in altered gene expression in ovarian granulosa cells isolated from in vivo preovulatory follicles. Endocrinology. 2013;154:2174–2187.
Boon RA, Vickers KC. Intercellular transport of microRNAs. Arterioscler Thromb Vasc Biol. 2013;33:186–192.
Team IS. Variations in reproductive events across life: a pooled analysis of data from 505,147 women across 10 countries. Hum Reprod. 2019;34(5):881–893.
Luborsky JL, Meyer P, Sowers MF, Gold EB, Santoro N. Premature menopause in a multi-ethnic population study of the menopause transition. Hum Reprod. 2003;18(1):199–206.
Takahashi TA, Johnson KM. Menopause. Med Clin North Am. 2015;99(3):521–534.
Committee opinion no. 605: primary ovarian insufficiency in adolescents and young women. Obstet Gynecol. 2014;124(1):193–197.
Jankowska K. Premature ovarian failure. Prz Menopauzalny. 2017;16(2):51–56.
Tao XY, Zuo AZ, Wang JQ, Tao FB. Effect of primary ovarian insufficiency and early natural menopause on mortality: a meta-analysis. Climacteric. 2016;19(1):27–36.
Archer DF. Premature menopause increases cardiovascular risk. Climacteric. 2009;12(Suppl 1):26–31.
Shuster LT, Rhodes DJ, Gostout BS, Grossardt BR, Rocca WA. Premature menopause or early menopause: long-term health consequences. Maturitas. 2010;65(2):161–166.
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2025 Camila Ponce Berrú, Pablo Sebastián Basantes Suárez, Fernando Israel Narváez Vásquez, Isabella Ponce Berrú
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
